Clinical Practice Guidelines for the Management of Congenital Syphilis in Japan, 2023: Executive Summary

Yoshinori Ito, Takuya Yamagishi, Chiaki Ikenoue, Naruhiko Ishiwada, Kenta Ito, Sota Iwatani, Kazunobu Ouchi, Kei Kawana, Hiroyuki Shimizu, Masayoshi Shinjoh, Noriko Takeuchi, Takeshi Tsugawa, Takanori Funaki, Munehiro Furuichi, Tadashi Hoshino, Hiroshige Mikamo, Isao Miyairi, Hiroyuki Moriuchi, Ichiro Morioka, Yuka YamagishiMasaaki Mori

研究成果: Review article査読

抄録

Congenital syphilis (CS) is a mother-to-child infection caused by the bacterium Treponema pallidum, transmitted through the placenta. In Japan, the number of syphilis cases has recently increased, accompanied by an increase in CS cases. Thus, automated methods for serum antibodies with serial values, without a 2× dilution sequence, have been widely used. Moreover, benzathine penicillin G was introduced in Japan in 2021. In response to the recent surge in CS, the first edition of the clinical practice guidelines for the management of CS was developed by a committee comprising representatives from 4 Japanese medical societies. This summary outlines 5 clinical questions with statements and expert comments regarding diagnosis, treatment and follow-up requirements. These guidelines aim to assist in the management of patients with CS infection.

本文言語English
ページ(範囲)e90-e94
ジャーナルPediatric Infectious Disease Journal
44
3
DOI
出版ステータスPublished - 2025 3月 1
外部発表はい

ASJC Scopus subject areas

  • 小児科学、周産期医学および子どもの健康
  • 微生物学(医療)
  • 感染症

フィンガープリント

「Clinical Practice Guidelines for the Management of Congenital Syphilis in Japan, 2023: Executive Summary」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル